[Use of the AgNOR method for the differential diagnosis of XXXX and for the quantification of non-neoplastic epidermal hyperproliferation in dermatohistology].

@entity82 @entity2517 @entity5 @entity1389 @entity8205 @entity6349 @entity19 @entity189 @entity1492 @entity10575 @entity272 @entity81 @entity320
The AgNOR number ( @entity10575 ) and the AgNOR quotient (NQ) of 228 melanocytic, epidermal and fibrohistiocytic lesions were investigated by image analysis. In @entity8205 , @entity6349 and Spitz nevi, significantly less AgNORs were seen than in malignant @entity320 and @entity320 in situ. Significant differences in AgNOR expression were detected between the subtypes of @entity320 , too. @entity189 showed a significantly higher AgNOR expression than keratoacanthomas and other @entity5 . Between the G1 @entity189 and the G2 and G3 groups, an increase of the @entity10575 and NQ was found. @entity2517 demonstrated a significantly lower AgNOR expression than @entity189 . Bowen--higher @entity10575 and NQ than the benign lesions. The lowest AgNOR results of fibrohistiocytic lesions were registered in regressive @entity81 and in scars, the highest in malignant @entity82 . Between dermato- @entity1492 protuberans, @entity1389 and malignant @entity82 , significant differences were found to exist. Furthermore we examined the suitability of the AgNOR technique for quantification of epidermal cell kinetics in non-neoplastic epidermal hyperproliferations. Especially in the grading of psoriasis this technique is helpful. First convincing results could be achieved for the use of the AgNOR method in the verification of antiproliferative effects of new substances in an experimental @entity19 tail test. This study demonstrated that the AgNOR technique in addition to the dermatohistological differential diagnosis of @entity5 is useful for the quantification of antiproliferative effects of different treatments in hyperproliferative @entity272 .
